MedTrace Logo

Stiripentol for the Treatment of Refractory Status Epilepticus

NCT06540378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-08-06

No results posted yet for this study

Summary

The investigators retrospectively analyzed all patients who were admitted to the Department of Neurology at Marburg University Hospital between 2013 and 2023 with a diagnosis of (super)-refractory status epilepticus and who received additional treatment of SE with STP. All patients who received STP during the SE were included, regardless of previous medication.

Conditions

  • Status Epilepticus

Interventions

DRUG

Stiripentol

Sponsors & Collaborators

  • University Hospital Marburg

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2023-12-31
Completion
2024-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06540378 on ClinicalTrials.gov